Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study

Table 1

Patients and tumor basic characteristics.

Characteristic	Total patients ()	Percentage
Age (years)
Median (range)	61 (33-80)
≥61	21	53.8%
<61	18	46.2%
Gender
Male	26	66.7%
Female	13	33.3%
ECOG performance status score
0-1	25	64.1%
2	14	35.9%
Primary lesion
Gastric	30	76.9%
Gastroesophageal junction	9	23.1%
Lines of previous treatment
1	4	10.3%
≥2	35	89.7%
Previous targeted drugs therapy
Yes	7	17.9%
No	32	82.1%
History of gastrectomy
Yes	17	43.6%
No	22	56.4%
Number of metastatic sites
≤2	9	23.1%
>2	30	76.9%
HER2 expression status
Positive	1	2.6%
Negative	17	43.6%
Not available	21	53.8%
Initial dosage of apatinib (mg)
500	22	56.4%
250	17	43.6%
PD-1 blockades
Camrelizumab	26	66.7%
Sintilimab	8	20.5%
Nivolumab	5	12.8%

Abbreviations: ECOG: Eastern Cooperative Oncology Group; HER2: human epidermal growth factor receptor 2; PD-1: programmed cell death protein 1.